JAGX — Jaguar Health Income Statement
0.000.00%
Last trade - 00:00- $7.33m
- $33.33m
- $11.69m
- 26
- 66
- 16
- 27
Annual income statement for Jaguar Health, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 9.38 | 4.33 | 12 | 9.76 | 11.7 |
| Cost of Revenue | |||||
| Gross Profit | 6.11 | 2 | 9.94 | 7.72 | 9.73 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 37.9 | 45.8 | 48.6 | 40.4 | 41.3 |
| Operating Profit | -28.5 | -41.5 | -36.6 | -30.6 | -29.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -33.8 | -52.6 | -48.4 | -41.9 | -39.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -33.8 | -52.6 | -48.4 | -41.9 | -39.3 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -33.8 | -52.6 | -47.5 | -41.3 | -38.5 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -38.6 | -52.6 | -47.5 | -41.3 | -38.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -10,982 | -5,052 | -2,070 | -116 | -135 |